EGFR and non-small cell lung carcinoma: First, this research is the first economic evaluation to compare the cost and clinical outcomes of sintilimab plus IBI305 and chemotherapy, and sintilimab plus chemotherapy versus chemotherapy alone in Chinese patients with EGFR-mutated NSCLC who have progressed on EGFR TKI treatment.